Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Report 2026

The fibrodysplasia ossificans progressiva (fop) treatment market size has grown strongly in recent years. It will grow from $0.5 billion in 2025 to $0.54 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to limited treatment options for rare bone disorders, increased rare disease awareness, growth in genetic research, expansion of specialty clinics, supportive regulatory frameworks.

The fibrodysplasia ossificans progressiva (fop) treatment market size is expected to see strong growth in the next few years. It will grow to $0.76 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to advancements in gene therapy drugs, increased orphan drug approvals, rising investment in rare disease research, improved diagnostic accuracy, expansion of personalized medicine. Major trends in the forecast period include rising focus on anti-inflammatory drug therapies, increased research in gene and molecular therapies, growing emphasis on early diagnosis and disease monitoring, expansion of rare disease clinical trials, improved multidisciplinary care approaches.

The growing adoption of gene therapy is expected to support the expansion of the fibrodysplasia ossificans progressiva (FOP) treatment market in the coming years. Gene therapy is a medical approach that modifies or replaces genes within a patient’s cells to treat or prevent disease. Its increasing adoption is driven by advances in genetic research, improved outcomes for conditions that were previously untreatable, and stronger regulatory backing for innovative therapeutic solutions. In the case of fibrodysplasia ossificans progressiva, gene therapy focuses on targeting and correcting mutations in the ACVR1 gene to help prevent abnormal bone formation. For example, in March 2024, according to the Bright Cell Healthcare Institute, a Vietnam-based regenerative medicine organization providing clinical-grade stem cell therapies, there were 36 FDA-approved gene therapies and approximately 500 candidates in development, with projections of 10-20 new approvals annually by 2025. Therefore, the rising adoption of gene therapy is driving the growth of the fibrodysplasia ossificans progressiva (FOP) treatment market.

Leading companies operating in the fibrodysplasia ossificans progressiva (FOP) treatment market are concentrating on the development of advanced therapies, including retinoid-based capsules, to address unmet medical needs by targeting the underlying genetic mutations linked to the condition and improving patient outcomes and quality of life. Retinoids are derivatives of vitamin A that are used therapeutically to regulate cell growth and support immune function, particularly in dermatological and certain oncological treatments. For instance, in August 2023, Ipsen, a France-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for its Sohonos capsules. This retinoid-based therapy is indicated for the treatment of fibrodysplasia ossificans progressiva and is designed to reduce the formation of new abnormal bone growth, known as heterotopic ossification. It offers an important treatment option for both adult and pediatric patients, helping to improve mobility and overall quality of life.

In March 2024, the International Fibrodysplasia Ossificans Progressiva Association (IFOPA), a US-based non-profit organization, entered into a partnership with Wazoku Crowd to strengthen research initiatives, provide greater support to affected families, and accelerate efforts toward finding a cure for fibrodysplasia ossificans progressiva. Through this collaboration, IFOPA aims to leverage Wazoku Crowd’s innovation and crowdsourcing capabilities to gather new ideas and solutions that can advance scientific understanding and treatment development for the disease. Wazoku Crowd is a UK-based innovation and crowdsourcing company that offers platforms enabling organizations to source ideas, insights, and innovations from a global community.

Major companies operating in the fibrodysplasia ossificans progressiva (fop) treatment market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., UCB S.A., Incyte Corporation, Ipsen Pharma, Alnylam Pharmaceuticals Inc., Blueprint Medicines Corporation, Ashibio, Ultragenyx Pharmaceutical Inc., Scholar Rock Holding Corporation, PTC Therapeutics Inc., Keros Therapeutics Inc., Biogen Inc.

North America was the largest region in the fibrodysplasia ossificans progressiva (FOP) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fibrodysplasia ossificans progressiva (fop) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fibrodysplasia ossificans progressiva (fop) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the fibrodysplasia ossificans progressiva (FOP) treatment market by increasing the cost of imported gene therapies, monoclonal antibodies, specialty pharmaceuticals, and clinical-grade reagents. Hospitals and research institutes in Asia-Pacific and Europe are most affected due to reliance on global biopharmaceutical supply chains. These higher costs can limit access to rare-disease therapies and slow clinical research programs. However, tariffs are encouraging regional production of orphan drugs and biologics, strengthening long-term treatment availability.

The fibrodysplasia ossificans progressiva (fop) treatment market research report is one of a series of new reports that provides fibrodysplasia ossificans progressiva (fop) treatment market statistics, including fibrodysplasia ossificans progressiva (fop) treatment industry global market size, regional shares, competitors with a fibrodysplasia ossificans progressiva (fop) treatment market share, detailed fibrodysplasia ossificans progressiva (fop) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fibrodysplasia ossificans progressiva (fop) treatment industry. This fibrodysplasia ossificans progressiva (fop) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fibrodysplasia ossificans progressiva (FOP) treatment involves medical approaches aimed at managing this rare genetic disorder in which soft tissues gradually ossify into bone. These interventions include medications, surgical procedures, and gene-based therapies to control symptoms, slow disease progression, reduce inflammation, limit additional bone formation, and enhance the quality of life for affected individuals.

The primary drug classes used in fibrodysplasia ossificans progressiva treatment include corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, and others. Corticosteroids are particularly effective in decreasing inflammation and regulating immune responses in various medical conditions. Treatment strategies for FOP consist of medication, surgery, and occupational therapy. These therapies can be administered through oral, topical, or parenteral routes and are utilized across hospitals, research institutes, and specialty clinics.

The fibrodysplasia ossificans progressiva (FOP) treatment market consists of revenues earned by entities by providing services such as supportive therapies, physical therapy, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The fibrodysplasia ossificans progressiva (FOP) treatment market also includes sales of bone morphogenetic protein (BMP) inhibitors, anti-inflammatory drugs, pain relievers, muscle relaxants, pain relievers, and muscle relaxants care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.